Researchers at Changzhou Hengbang Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described polypeptides acting as C5a anaphylatoxin chemotactic receptor 1 (C5aR; CD88) antagonists reported to be useful for the treatment of cancer, infections, cardiovascular disorders, endocrine disorders and immunological disorders.